Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test
Clinical narrative: It has been 3 days since he has tested positive for Covid-19; This spontaneous case was reported by a patient and describes the occurrence of COVID-19 (It has been 3 days since he has tested positive for Covid-19) in a male patient of an unknown age who received mRNA-1273 (Spikevax) for COVID-19 vaccination.     Concurrent medical conditions included Diabetes, COPD, Kidney cancer (Kidney cancer are in remission), Colon cancer (Colon cancer are in remission) and Cyst of kidney (Kidney cyst). Concomitant products included LOVASTATIN for an unknown indication.    On an unknown date, the patient received dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On an unknown date, the patient experienced COVID-19 (It has been 3 days since he has tested positive for Covid-19). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) at a dose of 1 dosage form twice a day. At the time of the report, COVID-19 (It has been 3 days since he has tested positive for Covid-19) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, SARS-CoV-2 test: positive (Positive) Positive.     The action taken with mRNA-1273 (Spikevax) (Unknown) was unknown.       It was reported that he usually takes lovastatin but was told by his hcp to stop the medication since he has been prescribed paxlovid, reported that he has been prescribed two kind of medications for his cough and other problems that he has. he picked up his prescription for paxlovid today 06jun2022 and noticed that the pi stated to tell your hcp if you have a history of kidney disease. he did not tell his hcp who prescribed him paxlovid about his medical history of kidney cancer and kidney cyst. He reported that his body feels good. He was asking if it was safe for him to take paxlovid due to was medical history of kidney cancer and kidney cyst? important dosing information in patients with renal impairment no dosage adjustment was needed in patients with mild renal impairment (egfr =60 to <90 ml/min). in patients with moderate renal impairment (egfr =30 to <60 ml/min). The dosage of paxlovid was  150 mg nirmatrelvir an 100 mg ritonavir twice daily for 5 days.  Company comment: This spontaneous case concerns a male patient of unspecified age with no relevant medical history reported, who experienced the unexpected non-serious adverse events of special interest, COVID-19 (It has been 3 days since he has tested positive for Covid-19) which occurred on unspecified day after a dose of mRNA-1273 vaccine(dose number not specified). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) twice daily for 5 days for COVID-19 treatment. Ongoing Covid 19 pandemic could be considered as confounder to the event. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed as per medical judgement.   Reporter did not allow further contact; Sender's Comments: This spontaneous case concerns a male patient of unspecified age with no relevant medical history reported, who experienced the unexpected non-serious adverse events of special interest, COVID-19 (It has been 3 days since he has tested positive for Covid-19) which occurred on unspecified day after a dose of mRNA-1273 vaccine(dose number not specified). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) twice daily for 5 days for COVID-19 treatment. Ongoing Covid 19 pandemic could be considered as confounder to the event. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report. Event seriousness assessed as per medical judgement.